Literature DB >> 22229124

The history of Parkinson's disease: early clinical descriptions and neurological therapies.

Christopher G Goetz1.   

Abstract

Although components of possible Parkinson's disease can be found in very early documents, the first clear medical description was written in 1817 by James Parkinson. In the mid-1800s, Jean-Martin Charcot was particularly influential in refining and expanding this early description and in disseminating information internationally about Parkinson's disease. He separated Parkinson's disease from multiple sclerosis and other disorders characterized by tremor, and he recognized cases that later would likely be classified among the Parkinsonism-plus syndromes. Early treatments of Parkinson's disease were based on empirical observation, and anticholinergic drugs were used as early as the nineteenth century. The discovery of dopaminergic deficits in Parkinson's disease and the synthetic pathway of dopamine led to the first human trials of levodopa. Further historically important anatomical, biochemical, and physiological studies identified additional pharmacological and neurosurgical targets for Parkinson's disease and allow modern clinicians to offer an array of therapies aimed at improving function in this still incurable disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22229124      PMCID: PMC3234454          DOI: 10.1101/cshperspect.a008862

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  26 in total

1.  FAMILIAL BILATERAL VASCULAR CALCIFICATION IN THE CENTRAL NERVOUS SYSTEM.

Authors:  G W BRUYN; G T BOTS; A STAAL
Journal:  Psychiatr Neurol Neurochir       Date:  1964 Jul-Aug

2.  STRIATO-NIGRAL DEGENERATION.

Authors:  R D ADAMS; L VANBOGAERT; H VANDEREECKEN
Journal:  J Neuropathol Exp Neurol       Date:  1964-10       Impact factor: 3.685

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  Basal ganglia calcification, hypoparathyroidism, and extrapyramidal motor manifestations.

Authors:  M D Muenter; J P Whisnant
Journal:  Neurology       Date:  1968-11       Impact factor: 9.910

5.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

6.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.

Authors:  R de la Fuente-Fernández; T J Ruth; V Sossi; M Schulzer; D B Calne; A J Stoessl
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

9.  Dopamine miracle: from brain homogenate to dopamine replacement.

Authors:  Oleh Hornykiewicz
Journal:  Mov Disord       Date:  2002-05       Impact factor: 10.338

10.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

View more
  65 in total

1.  Why our patients (and we) need basic science research.

Authors:  Nina F Schor
Journal:  Neurology       Date:  2013-05-28       Impact factor: 9.910

2.  Advance modern medicine with clinical case reports.

Authors:  Yì-Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2014-12

3.  Enhanced differentiation of human dopaminergic neuronal cell model for preclinical translational research in Parkinson's disease.

Authors:  Dilshan S Harischandra; Dharmin Rokad; Shivani Ghaisas; Saurabh Verma; Alan Robertson; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-08-20       Impact factor: 5.187

4.  URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.

Authors:  Angel Escamilla-Ramírez; Esperanza García; Guadalupe Palencia-Hernández; Ana Laura Colín-González; Sonia Galván-Arzate; Isaac Túnez; Julio Sotelo; Abel Santamaría
Journal:  Neurotox Res       Date:  2017-01-14       Impact factor: 3.911

5.  Visual Hallucinations and Impulse Control Disorder in Parkinson's Disease.

Authors:  Nadia S Hejazi
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-10       Impact factor: 5.176

6.  Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.

Authors:  William B Lynch; Christopher W Tschumi; Amanda L Sharpe; Sarah Y Branch; Cang Chen; Guo Ge; Senlin Li; Michael J Beckstead
Journal:  Mov Disord       Date:  2018-11-15       Impact factor: 10.338

7.  Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration.

Authors:  Arati A Inamdar; Muhammad M Hossain; Alison I Bernstein; Gary W Miller; Jason R Richardson; Joan Wennstrom Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

8.  Emergence of nonmotor symptoms as the focus of research and treatment of Parkinson's disease: introduction to the special section on nonmotor dysfunctions in Parkinson's disease.

Authors:  Alice Cronin-Golomb
Journal:  Behav Neurosci       Date:  2013-04       Impact factor: 1.912

Review 9.  miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Mazin A Zamzami; Hani Choudhry; Munvar M Shaik; Ian A Tamargo; Mohammad A Kamal
Journal:  Med Chem       Date:  2016       Impact factor: 2.745

10.  Conditioning Against the Pathology of Parkinson's disease.

Authors:  Rehana K Leak
Journal:  Cond Med       Date:  2018-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.